The ESMO Congress 2021, the most influential oncology platform in Europe, is about to open: from September 16th to 21st, the virtual platform of the Congress will present the latest advances in oncology. This year the virtual format will be enhanced, to guarantee a more visual and user-friendly experience in a context that reminds face-too- face events.
The scientific programme is very rich as usual, with three presidential symposiums to discuss data emerging from relevant trials in breast, colorectal and prostate cancer where new combinations of chemo and immunotherapy have been tested; studies on the impact of SARS-CoV-2 and vaccines in cancer patients will also be discussed and there’ll be the opportunity to learn about latest advances in therapies for less common cancers too, such as pheochromocytoma or paragangliomas.
Michelangelo Foundation will also give an important contribution to the congress: on Monday, September 20th at 5.30 pm, during the Mini oral session on early stage breast cancer, Giampaolo Bianchini of the Department of Medical Oncology – San Raffaele Hospital in Milan will discuss the latest data from a translational study carried out on patients enrolled in the NeoTRIPaPDL1 trial, a study sponsored and conducted by Michelangelo Foundation. This is a phase III clinical trial to evaluate the effects of neoadjuvant therapy with an antibody against PDL-1 in patients with locally advanced triple-negative breast cancer undergoing treatment with nab-paclitaxel and carboplatin; data on predictive value of gene expression profiles and their dynamics during therapy will be presented during ESMO congress.